$2.59-7.5%Nov 13 close
Reported results on November 13, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 12, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$2.3M | -$2M | -18.78% |
| Profit per share | -$1.12 | -$2.94 | +61.90% |
| Free Cash Flow | -$1.6M | -$2.2M | +24.84% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Bluejay Diagnostics, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The third quarter marked significant progress for Bluejay as we advanced several critical elements toward regulatory submission and commercialization,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Diagnostics: Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony™ System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony™ can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com. 2
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Bluejay Diagnostics, Inc.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.